{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:50:11Z","timestamp":1747165811718,"version":"3.40.5"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jpsmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pain and Symptom Management"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jpainsymman.2024.06.024","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T21:23:08Z","timestamp":1720041788000},"page":"e340-e342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute Urinary Frequency in a Cancer Patient on Olanzapine"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8402-0794","authenticated-orcid":false,"given":"Kristy","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Bruera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2009","series-title":"Zyprexa (olanzapine) [package insert]","key":"10.1016\/j.jpainsymman.2024.06.024_bib0001"},{"key":"10.1016\/j.jpainsymman.2024.06.024_bib0002","unstructured":"Zyprexa, (olanzapine) [summary of product characteristics \u2013 european medicines agency]., Eli Lilly; Indianapolis, IN."},{"key":"10.1016\/j.jpainsymman.2024.06.024_bib0003","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11864-020-00804-1","article-title":"The benefits of olanzapine in palliating symptoms","volume":"22","author":"Davis","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jpainsymman.2024.06.024_bib0004","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1200\/JCO.23.01280","article-title":"Cancer cachexia expert panel. cancer cachexia: ASCO guideline rapid recommendation update","volume":"41","author":"Roeland","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2024.06.024_bib0005","unstructured":"World Health Organization. ICD-11 for mortality and morbidity statistics. 2024. Available from: https:\/\/icd.who.int\/browse\/2024-01\/mms\/en#403610249e. Accessed June 13, 2024."},{"key":"10.1016\/j.jpainsymman.2024.06.024_bib0006","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jpainsymman.2024.06.024_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.02.2009.1547","article-title":"Antipsychotic-induced urinary dysfunction: anticholinergic effect or otherwise?","volume":"2009","author":"Saddichha","year":"2009","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jpainsymman.2024.06.024_bib0008","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/nau.24695","article-title":"Urinary side effects of psychotropic drugs: a systematic review and metanalysis","volume":"40","author":"Trinchieri","year":"2021","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.jpainsymman.2024.06.024_bib0009","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.amjopharm.2007.09.003","article-title":"Olanzapine and acute urinary retention in two geriatric patients","volume":"5","author":"Cohen","year":"2007","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.jpainsymman.2024.06.024_bib0010","first-page":"146","article-title":"Olanzapine as a cause of urinary incontinence: a case report","volume":"7","author":"Dada","year":"2012","journal-title":"Iran J Psychiatry"},{"key":"10.1016\/j.jpainsymman.2024.06.024_bib0011","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/02537176221111581","article-title":"Olanzapine-associated chronic urinary retention and ciliochoroidal effusion: rare adverse effects of a commonly prescribed antipsychotic","volume":"45","author":"Purohith","year":"2023","journal-title":"Indian J Psychol Med"},{"key":"10.1016\/j.jpainsymman.2024.06.024_bib0012","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/WNF.0b013e318157e462","article-title":"Urinary retention during combined treatment of postpsychotic depression with duloxetine and olanzapine","volume":"31","author":"Englisch","year":"2008","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.jpainsymman.2024.06.024_bib0013","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1592\/phco.29.1.64","article-title":"Antipsychotic-induced hyperprolactinemia","volume":"29","author":"Bostwick","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jpainsymman.2024.06.024_bib0014","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/j.1523-1755.2005.00586.x","article-title":"Prolactin, a natriuretic hormone, interacting with the renal dopamine system","volume":"68","author":"Ibarra","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.jpainsymman.2024.06.024_bib0015","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","article-title":"Prolactin: structure, function, and regulation of secretion","volume":"80","author":"Freeman","year":"2000","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jpainsymman.2024.06.024_bib0016","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/ki.1976.90","article-title":"Osmotic control of prolactin release and its effect on renal water excretion in man","volume":"10","author":"Berl","year":"1976","journal-title":"Kidney Int"},{"key":"10.1016\/j.jpainsymman.2024.06.024_bib0017","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000499694","article-title":"Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia","volume":"109","author":"Vilar","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.jpainsymman.2024.06.024_bib0018","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/ccr3.2396","article-title":"Medication-induced obstructive uropathy and hyperprolactinemia in a pediatric patient","volume":"7","author":"Nkansah-Amankra","year":"2019","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.jpainsymman.2024.06.024_bib0019","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4274\/jus.galenos.2018.2436","article-title":"Tamsulosin-induced hyperprolactinemia in a patient with multiple sclerosis: a case report","volume":"6","author":"Gorgel","year":"2019","journal-title":"J Urol Surg"}],"container-title":["Journal of Pain and Symptom Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392424008455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392424008455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T21:24:59Z","timestamp":1726781099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0885392424008455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0885392424008455"],"URL":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2024.06.024","relation":{},"ISSN":["0885-3924"],"issn-type":[{"type":"print","value":"0885-3924"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Urinary Frequency in a Cancer Patient on Olanzapine","name":"articletitle","label":"Article Title"},{"value":"Journal of Pain and Symptom Management","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2024.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine.","name":"copyright","label":"Copyright"}]}}